Summary
This 2018 GWAS meta-analysis identified novel genetic loci associated with lifetime cannabis use and demonstrated substantial genetic overlap with psychiatric conditions, particularly schizophrenia. Using large international cohorts, the authors employed Mendelian randomisation to investigate bidirectional causality, as suggested by the title finding a causal effect of schizophrenia liability on cannabis use. The work contributes to understanding shared genetic architecture between substance use and mental health phenotypes.
UK applicability
Findings are relevant to UK public health policy and psychiatric research communities, particularly for understanding genetic predisposition to cannabis use and mental health comorbidity in the British population. The genetic architecture identified may inform stratified prevention strategies in UK clinical practice, though environmental and social factors remain critical contextual determinants.
Key measures
SNP-based heritability estimates, genetic correlation coefficients between cannabis use and psychiatric traits, causal effect estimates using Mendelian randomisation
Outcomes reported
The study conducted a genome-wide association study (GWAS) to identify genetic loci associated with lifetime cannabis use and examined genetic overlap with psychiatric traits, particularly schizophrenia. The analysis as suggested by the title investigated whether schizophrenia liability has a causal effect on cannabis use initiation.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.